CORE A: CELL AND GENE THERAPY CLINICAL MANUFACTURE AND MONITORING CORE Abstract This is the second revision of a Core that was initially reviewed favorably and rated Superior, but then was rated Satisfactory in the Al submission. The Core includes investigators with ample expertise in the regulatory filing and the conduct of investigator-initiated gene and cell therapy clinical trials. Relevant prior clinical trials conducted by Core A investigators include tumor infiltrating lymphocyte (TIL) gene marking using retrovirus, hematopoietic stem cell (HSC) genetic modification using retrovirus, and dendritic cell (DC)-based clinical trials both with tumor antigen peptide pulsing and adenoviral transduction. The generation of cell and gene therapy products is enabled by an existing and fully functional clinical Good Manufacturing Practices (GMP) suite, which includes both positive and negative pressure rooms for cellular and gene therapy product manufacture, respectively. Institutional oversight committees, Compliance Officers and auditors provide the adequate framework for the conduct of such investigator-initiated clinical trials. An important role of the Core is the analysis of immune responses in cancer immunotherapy. The Core has focused on assay standardization, use of quantitative measures and definition of changes from baseline parameters that are beyond the assay variability with high statistical confidence. These modern immune monitoring assays are fully implemented and routine in the Core, including MHC tetramer, ELISPOT, intracellular cytokine staining and intracellular phosphorylated signaling molecule flow cytometry. Based on this expertise, the Core will provide support for all projects of this Program Project Grant (PPG).
In Aim 1 the Core will manage the two clinical grade vectors that will b^ used in the clinical trials proposed in Projects 1 and 3.
In Aim 2 the Core will manufacture the cellular therapy products for the clinical trials proposed in Projects 1 and 3, including the genetically modified peripheral blood mononuclear cells (PBMC) and HSC.
In Aim 3 the Core provides expertise in immune monitoring assays for all of this PPG. In this revised application we have detailed the information on the lot release testing of TCR transgenic cells, and we provide evidence that we can routinely gate and detect both CDS and CD4 cells expressing TCRs and intracellular staining for cytokine production using multicolor flow cytometry.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA132681-04
Application #
8448004
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
Budget Start
2013-03-01
Budget End
2014-02-28
Support Year
4
Fiscal Year
2013
Total Cost
$438,766
Indirect Cost
Name
California Institute of Technology
Department
Type
DUNS #
009584210
City
Pasadena
State
CA
Country
United States
Zip Code
91125
Fendler, Wolfgang Peter; Barrio, Martin; Spick, Claudio et al. (2016) 68Ga-DOTATATE PET/CT interobserver agreement for neuroendocrine tumor assessments: results from a prospective study on 50 patients. J Nucl Med :
Boschi, Stefano; Lee, Jason T; Beykan, Seval et al. (2016) Synthesis and preclinical evaluation of an Al(18)F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand. Eur J Nucl Med Mol Imaging 43:2122-2130
Bethune, Michael T; Gee, Marvin H; Bunse, Mario et al. (2016) Domain-swapped T cell receptors improve the safety of TCR gene therapy. Elife 5:
Bluemel, Christina; Krebs, Markus; Polat, Bülent et al. (2016) 68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT. Clin Nucl Med 41:515-21
Fiacco, Stephen V; Kelderhouse, Lindsay E; Hardy, Amanda et al. (2016) Directed Evolution of Scanning Unnatural-Protease-Resistant (SUPR) Peptides for in Vivo Applications. Chembiochem 17:1643-51
Fendler, Wolfgang Peter; Czernin, Johannes; Herrmann, Ken et al. (2016) Variations in PET/MRI Operations: Results from an International Survey Among 39 Active Sites. J Nucl Med 57:2016-2021
Spick, Claudio; Herrmann, Ken; Czernin, Johannes (2016) 18F-FDG PET/CT and PET/MRI Perform Equally Well in Cancer: Evidence from Studies on More Than 2,300 Patients. J Nucl Med 57:420-30
Fang, Jinxu; Hu, Biliang; Li, Si et al. (2016) A multi-antigen vaccine in combination with an immunotoxin targeting tumor-associated fibroblast for treating murine melanoma. Mol Ther Oncolytics 3:16007
Mok, Stephen; Tsoi, Jennifer; Koya, Richard C et al. (2015) Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition. BMC Cancer 15:356
Herrmann, Ken; Bluemel, Christina; Weineisen, Martina et al. (2015) Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy. J Nucl Med 56:855-61

Showing the most recent 10 out of 58 publications